T here are a growing number of prognostic models and scales designed to predict mortality or other outcomes after acute stroke. [1] [2] [3] [4] [5] [6] [7] [8] Although many of the scales have favorable properties reported, few have been incorporated into routine clinical practice. Two common limitations in prognosis research are failure to modify scales with new covariates that may improve the performance and lack of external validation of scales in independent cohorts. Furthermore, the usefulness of SOAR beyond inpatient stay is not examined previously.
In this study, we aimed to evaluate whether including a measure of initial stroke severity (NIHSS) to form a modified-SOAR (mSOAR) score would improve the prognostic accuracy and also assessed that this would be applicable ≤90 days post stroke in an independent data set.
Methods

SOAR Score
The description for the original SOAR score's derivation has been published elsewhere. 11 Briefly, the SOAR score is an 8-point scale (0-7; Table 1 ). The total SOAR score is the sum of points allocated for each of the input variables, all measured at the time of admission.
Derivation of mSOAR Score
Data Source
We conducted a retrospective analysis on routine clinical database held as part of the Anglia Stroke and Heart Clinical Network (ASHCN), which recorded consecutive stroke admissions between 2008 and 2011 and followed up till hospital discharge. The registry is in a geographical area of England and includes 8 National Health Service hospitals in Norfolk, Suffolk, and Cambridgeshire. Of note, most in-hospital deaths in ASHCN occurred within 90 days; 81% of within 90-day deaths were in-hospital deaths in the Anglia Stroke Network Evaluation Study (ASCNES), 15 the participants of which were drawn from ASHCN database.
All patients included were confirmed stroke cases aged ≥18 years based on expert multidisciplinary clinical assessment informed by neuroimaging and other investigations as per usual clinical practice. All included patients were treated as per institutional practice and stroke guidelines. Relevant institutional and ethical approvals of use of ASHCN data were obtained as part of ASCNES. 15 Conduct and reporting of our analysis are in accordance with the UK Medical Research Council Prognosis Research Strategy (PROGRESS) Partnership best practice guidance. 16 
Participants and Variables
We included patients for whom we had baseline demographic and outcome information to designate our prognostic scales and chosen outcome. Variables included to calculate SOAR and mSOAR scales were age (years), stroke subtype (ischemic or hemorrhagic, based on clinical and neuroimaging finding), oxford stroke classification project classification (total or partial anterior circulation, posterior circulation, or lacunar strokes), prestroke modified Rankin Scale (mRS), and baseline NIHSS at the time of first assessment on hospital arrival. Outcome of interest was all-cause mortality censored at discharge. The length of stay for individuals who lived was a median of 9 (interquartile range [IQR], 5-19) days and for those who died, 10 (IQR, 5-27) days.
External Validation
We validated mSOAR score performance using pooled data from 2 independent prospective observational studies performed in Glasgow, United Kingdom. 17, 18 The process for the validation was equivalent to that used in the derivation studies. We included those stroke patients with relevant baseline and 90-day mortality data. In 1 data set, initial stroke severity was assessed using Scandinavian Stroke Scale rather than NIHSS. We transformed Scandinavian Stroke Scale into NIHSS using a validated process.
19
Statistical Methods
We used standard descriptive statistics for the cohort. We described mean (SD) or median (IQR) for continuous variables and count (percentage) for categorical variables. To assign an integer score for baseline NIHSS into the modified-SOAR score, we categorized the NIHSS scores into 4 categories: 1 to 4, 5 to 10, 11 to 20, and ≥21. The designated integer values for baseline NIHSS score were obtained by rounding the log odds ratios to the nearest integer. 15 To keep scoring aligned with original SOAR scores, we further collapsed NIHSS categories 11 to 20 and >20 into a single category of >11 (Table I in the online-only Data Supplement).
We calculated odds ratios and 95% confidence intervals (CIs) for early (90 days) mortality using univariable and multivariable logistic regression models. Associated P values were calculated using the Cochrane-Mantel-Haenszel test.
Outcome of interest is early mortality. We compared discrimination of SOAR and mSOAR using c-statistics (area under the receiver operating curve [AUROC]) for each scale. We calculated the net reclassification index (NRI) and the integrated discrimination improvement as a result of adding NIHSS to the original SOAR score. The NRI measures the correctness of reclassification of subjects based on their predicted probabilities of events using the new model with the option of imposing meaningful risk categories. 20, 21 The integrated discrimination improvement measures the new model's improvement in average sensitivity without sacrificing average specificity. 20, 21 NRI and integrated discrimination improvement are methods to measure the increase (or decrease) in predicted probabilities for those who have (or have not) an event of interest. 20, 21 We assessed calibration using Hosmer-Lemeshow goodness-of-fit tests. We also performed the sensitivity analysis in the validation cohort for outcome of mortality within 10 days.
Analyses were undertaken using SAS version 9.3 (SAS Institute Inc, Cary NC) and Stata version 11.0 (Stata Corporation, College Station, TX). Data are presented as per SOAR and mSOAR scoring. LACS indicates lacunar stroke; mRS, modified Rankin Scale; mSOAR, modified-stroke subtype, Oxfordshire Community Stroke Project Classification, age, and prestroke modified Rankin; NIHSS, National Institutes of Health Stroke Scale; OCSP, oxford stroke classification project; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; and TACS, total anterior circulation stroke.
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Results
Derivation Cohort
Of the 8756 total patients with acute stroke in the ASHCN registry (2008-2011), we used data for 1002 (11%) patients, who had complete baseline data for individual items of the SOAR/mSOAR scores. The main missing variable was NIHSS as this was not routinely assessed. The characteristics of those with NIHSS observed and those with missing NIHSS data within the ASHCN registry during the study period are shown in Table II in the online-only Data Supplement.
The cohort with complete baseline data to form the SOAR/ mSOAR scores had a median age of 78 (IQR, 69-85) years; 465 (46%) were women; median baseline NIHSS score of 6 (3-13; Table 1 ). One hundred five (10.5%) patients died as inpatients ( Table 2 ). The median SOAR score was 2 (IQR, 1-3). The proportions of early mortality post stroke varied according to the original SOAR scores (Table III in the online-only Data Supplement).
The median mSOAR score for the cohort was 3 (IQR, 2-5). The proportions of early death post stroke varied according to individual modified-SOAR scores from 1% early mortality for an mSOAR score of 0 to 1 to 49% early mortality for an mSOAR score of 7 ( Table 2 ). The observed risks for increasing the value of the mSOAR score in Table 2 were similar to those predicted from the logistic regression model. The predicted values for each mSOAR score, 0 to 7, were 1.0%, 1.5%, 6.5%, 9.2%, 19.5%, 26.2%, and 49.2%, respectively. These values are close to the observed risks and hence we have based our predicted values on the observed risks of the derivation cohort.
Prognostic accuracy metrics (sensitivity, specificity, positive, and negative predictive values) for predicting early mortality varied according to mSOAR score with a tradeoff between sensitivity and specificity particularly evident at extremes of scoring (Table 3 ). The mSOAR score that seemed to show optimal prognostic accuracy was at cutoff score of 3 (ie, mSOAR score, ≥4).
The discrimination of the original SOAR and mSOAR scores, using AUROC, was 0.79 (95% CI, 0.75-0.84) and 0.83 (95% CI, 0.79-0.86), respectively, with a significant difference in favor of mSOAR (P=0.001; Figures I and Figure II in online-only Data Supplement; Figure 1 ). Calibration, which suggested the mSOAR model gave reasonable fit to the data, was good (P=0.67 for the Hosmer-Lemeshow test).
Validation Cohort
The 2 studies that comprised the external validation cohort included 1091 patients of whom 1012 (93%) had full data to allow SOAR/mSOAR scoring and outcome analyses. The remaining patients were excluded because of missing data. The median age of the validation cohort was 71 (IQR, 61-79) years; with 497 (49%) were women and median baseline NIHSS was 5 (IQR, 2-11; Table 1 ). One hundred twenty-one (12.0%) patients died within 90 days post stroke ( Table 2) .
The median original SOAR score for the validation cohort was 1 (IQR, 1-2). In contrast, the median mSOAR score for similar cohort was 2 (IQR, 1-4). The proportions of early death post stroke varied according to mSOAR scores from 3% for mSOAR scores of 0 to 1 to 42% for an mSOAR score of 7 ( Table 2 ). The AUROC of the modified-SOAR score performed using the validation cohort was 0.84 (95% CI, 0.82-0.88) for outcome of early mortality. Calibration suggested that the mSOAR model gave a reasonable fit to the data (P=0.70 for the Hosmer-Lemeshow test; Figure 2 ).
For the derivation cohort, the NRI was 66.7% (n=547 recoded to a lower risk category and n=76 recoded to a higher risk category). For the validation cohort, the NRI was 62.5% (n=662 recoded to lower risk and n=78 recoded to higher risk; Tables IV and V in the online-only Data Supplement). The integrated discrimination improvement in sensitivity across 
Sensitivity Analysis
Results of sensitivity analysis performed on the validation cohort for outcome of mortality within 10 days post stroke are available in Table VI 
Discussion
Our findings suggest that the addition of an initial stroke severity scale (NIHSS) may significantly improve prognostic accuracy of the SOAR score for predicting early mortality post stroke. We think that our modified mSOAR score offers prognostic utility while remaining relatively easy to score. A criticism of previous studies that have suggested favorable properties of prognostic tools has been the lack of replication. We performed validation analyses using an independent and geographically distinct population. Prognostic utility of mSOAR was confirmed in this cohort.
Although several stroke prognosis scales are described, few have been adopted for widespread clinical use. An example of a prognostic tool that has translated into practice is the ABCD 2 (age, blood pressure, clinical features and duration of TIA, diabetes) risk score for transient ischemic attack. 22 We think that mSOAR shares several features with ABCD 2 that should make it attractive to clinical teams. The input covariates of mSOAR are easily available; in fact, most of the features needed to score mSOAR are recorded as standard in national stroke audits. We recognize that premorbid mRS is an imperfect measure, but it remains the most common method of describing prestroke functioning. 23 Furthermore, we and others have previously shown that prestroke mRS is an independent predictor of stroke outcomes, such as mortality and length of stay. 24, 25 Creating a total mSOAR score is also straightforward with only 5 variables requiring scoring and no need of external software or complicated arithmetic. Derivation and validation of mSOAR score were based on a heterogeneous population, and so the score should be applicable to all stroke syndromes.
Our study had a specific hypothesis around adding a marker of initial stroke severity to an existing prognostic tool. We recognized that stroke impairment measures, such as NIHSS, have prognostic value as a standalone assessment, and so intuitively adding these data to SOAR should improve properties. Our approach could be applied to any of the other stand alone or multivariate prognostic tools available in acute stroke. Indeed, future prognostic research in stroke requires further examination of which are the best predictors of various relevant outcomes, including mortality and functional outcome, both as standalone and as part of multivariable predictive tools. Perhaps, inclusion of other covariates especially more sophisticated or clinically relevant variables would improve the prognostic value. For example, the addition of neuroimaging finding to the ABCD 2 score 22 (which resulted in ABCD 3 -I score 26 ) improves the risk stratification after transient ischemic attack in secondary care settings. 26 Another example is the widely used and well-validated Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score, which includes time delay from stroke onset to admission, specific clinical signs at presentation, and baseline glucose level. 8, 27 It would also be informative to compare clinical utility of mSOAR against intuition of an experienced clinician. Future prognostic research perhaps should focus on using large composite datasets with comprehensive baseline data that would allow for such an analysis and help describe an optimal predictive covariate set for relevant outcomes.
We describe an optimal performing cut point for our scale; this is the point of most equitable trade-off between false positives and false negatives. In practice, the mSOAR score that has the greatest utility will vary according to the purpose for which the score is used. For example, if clinicians wish to use the prognostic information to inform discussions around ceilings of care, they may prefer a cut point on the scale that minimizes false positives. A difficulty with mSOAR and indeed all stroke prognostic scales is how the clinician uses the tool. If decisions on pursuing or withholding treatment are to be based on a risk estimate then that estimate needs to be robust. Although mSOAR has favorable properties, that are comparable or better than many other prognostic tools, it is probably still not suitable as the sole basis for therapeutic decisions. Even at the optimal performing cut point, mSOAR will suggest early mortality for a substantial proportion who go on to survive past 90 days and equally will suggest survival for a proportion who have early mortality. Nonetheless, patients and families want early prognostic information, and clinicians have to make therapeutic decisions based on likely prognosis each day. We think that mSOAR offers some structure and evidence base to inform prognostic assessment.
We agree that the NRI seems high. The NRI works best for dichotomous data. 20, 21 The majority of the reclassifications in our data were within the low-risk categories; hence, the practical importance of these reclassifications will be limited. Thus, we think that the NRI should be interpreted with caution and prefer the ROC as a better measure of the difference between the risk scores.
Strengths of our analysis include the large sample size, large number of outcomes, and real-world populations. We think that our results will have greater external validity than prognostic scores derived and validated exclusively using selected clinical trial participants. Furthermore, for the first time, we found that SOAR and mSOAR are useful ≤90 days post stroke mortality prediction. Despite the observable differences between the derivation and validation cohorts in terms of age and prestroke mRS and the follow-up time points (inhospital versus within 90 days), the mSOAR score performed similarly and consistently, which may indicate its generalizability.
A limitation of our derivation data set was substantial missing NIHSS data. Our analysis comparing those with and without NIHSS suggests that missing NIHSS data were more likely to be associated with markers of poor outcome (age and prestroke mRS) and higher in-hospital mortality, approximately doubled the mortality risk. The data we used for our derivation work were from a clinical registry. At the time of data collection, NIHSS assessment and recording in the registry were not mandatory. We acknowledge that those with NIHSS recorded may be systematically different from those without; however, the derivation cohort still has a spread of NIHSS and outcomes that are in keeping with data from other registries and so seem to have external validity. The effect of missing NIHSS could potentially bias the prognostic properties of mSOAR, but we are reassured that in our validation cohort (with good data capture for NIHSS), the properties of mSOAR were similar to the derivation data. We also hope that the effect of any misreporting of key variables will be modest given our relatively large and similar size data sets for derivation and validation and the internal and external quality control used within such national registries. The final cohorts are all old, and changes in stroke care may have affected early mortality and hence the properties of the tool. Of note, the derivation data were based on in-hospital mortality, and we were unable to ascertain their vital status at 90 -days. Nevertheless, examination of ASCNES data (drawn from the same ASHCN database) with 1-year follow-up data demonstrated that 81% of within 90 days were in-hospital deaths.
In conclusion, our results demonstrate the reliability of modified-SOAR score to predict early death in an acute stroke cohort. Adding NIHSS data to the original SOAR score, to create modified-SOAR score, improved the prognostic utility in both derivation and validation data sets. Modified SOAR may potentially help clinicians better predict early stroke mortality.
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Supplementary Figure I : Area under the receiving operator curve (AUROC) of the original SOAR score for early mortality in the derivation cohort.
